-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

Benzinga·07/27/2026 10:27:24
Listen to the news
Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.